Netramark Holdings Inc (TSE:AIAI) has released an update.
NetraMark Holdings Inc. is set to reveal groundbreaking data at the AD/PD™ 2024 conference, showcasing how its AI-powered NetraAI can identify crucial biomarkers for Parkinson’s disease, potentially leading to more effective treatments. The company’s unique AI solution, which excels in analyzing small datasets to avoid overfitting and generate actionable insights, could significantly improve the success rate of clinical trials. NetraMark’s innovative approach promises to enhance our understanding of Parkinson’s by detecting subtypes and biological markers critical to disease progression.
For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.
